Compare · MGX vs MRNA
MGX vs MRNA
Side-by-side comparison of Metagenomi Therapeutics Inc. (MGX) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MGX and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $19.36B, about 359.6x MGX ($53.8M).
- Over the past year, MGX is down 0.7% and MRNA is up 102.6% - MRNA leads by 103.3 points.
- MRNA has been more active in the news (15 items in the past 4 weeks vs 3 for MGX).
- MRNA has more recent analyst coverage (25 ratings vs 8 for MGX).
- Company
- Metagenomi Therapeutics Inc.
- Moderna Inc.
- Price
- $1.44+2.86%
- $48.76+4.37%
- Market cap
- $53.8M
- $19.36B
- 1M return
- +5.49%
- -2.68%
- 1Y return
- -0.69%
- +102.64%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2018
- News (4w)
- 3
- 15
- Recent ratings
- 8
- 25
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest MGX
- SEC Form DEFA14A filed by Metagenomi Therapeutics Inc.
- SEC Form DEF 14A filed by Metagenomi Therapeutics Inc.
- Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
- SEC Form 4 filed by Irish Jian
- SEC Form 4 filed by Wein Matthew
- SEC Form 4 filed by Wapnick Pamela
- Chief Financial Officer Wapnick Pamela sold $2,530 worth of shares (1,581 units at $1.60), decreasing direct ownership by 0.84% to 187,375 units (SEC Form 4)
- Officer Wein Matthew sold $771 worth of shares (482 units at $1.60), decreasing direct ownership by 0.42% to 114,549 units (SEC Form 4)
- Chief Executive Officer Irish Jian gifted 228,462 shares and sold $2,571 worth of shares (1,607 units at $1.60), decreasing direct ownership by 41% to 333,770 units (SEC Form 4)
- SEC Form S-8 filed by Metagenomi Therapeutics Inc.
Latest MRNA
- Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
- Director Horning Sandra converted options into 16,233 shares, increasing direct ownership by 690% to 18,585 units (SEC Form 4)
- Director Rubenstein David M. converted options into 8,116 shares, increasing direct ownership by 531% to 9,643 units (SEC Form 4)
- Director Hussain Abbas sold $264,952 worth of shares (5,682 units at $46.63) as part of a pre-agreed trading plan and converted options into 16,233 shares, increasing direct ownership by 696% to 12,066 units (SEC Form 4)
- Director Nabel Elizabeth G converted options into 16,233 shares, increasing direct ownership by 526% to 19,317 units (SEC Form 4)
- Director Nader Francois converted options into 12,174 shares, increasing direct ownership by 59% to 32,781 units (SEC Form 4)
- Director Tallett Elizabeth E converted options into 4,058 shares, increasing direct ownership by 577% to 4,761 units (SEC Form 4)
- SEC Form 10-Q filed by Moderna Inc.
- Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
- Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate